Sugi Predict

Sugi Predict / Compounds / SCHEMBL1129355

SCHEMBL1129355

SCHEMBL1129355

Fc1cccc(F)c1Oc1ccc(Br)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.45
▸ LPAR1 Q92633 3/20 0.40
▸ LPAR5 Q9H1C0 3/20 0.40
▸ SLC6A2 P23975 3/20 0.39
▸ SLC6A4 P31645 2/20 0.39
▸ SLC6A3 Q01959 2/20 0.39
▸ HTR1A P08908 1/20 0.39
▸ DHODH Q02127 1/20 0.38
▸ EPAS1 Q99814 1/20 0.37
▸ CES2 O00748 1/20 0.36
▸ CES1 P23141 1/20 0.36
▸ MCL1 Q07820 1/20 0.35
▸ GCK P35557 2/20 0.35
▸ CYP2A6 P11509 1/20 0.35
▸ MAOA P21397 1/20 0.34
▸ MAOB P27338 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17423587 1.00 MAPT (0.45) MAPTLPAR1LPAR5SLC6A2SLC6A4
SCHEMBL1129084 0.84 AR (0.51) MAPTLPAR1LPAR5SLC6A2SLC6A4
SCHEMBL15897482 0.81 DHODH (0.50) LPAR1LPAR5DHODHCES2CES1
SCHEMBL13861391 0.78 LPAR1 (0.40) MAPTLPAR1LPAR5SLC6A2SLC6A4
SCHEMBL21486338 0.78 TEAD4 (0.45) MAPTLPAR1LPAR5SLC6A2SLC6A4
SCHEMBL15515736 0.78 ALDH1A1 (0.54) MAPTLPAR1LPAR5MAOAMAOB
SCHEMBL5539624 0.78 LPAR1 (0.40) MAPTLPAR1LPAR5SLC6A2SLC6A4
SCHEMBL30866995 0.78 SLC6A2 (0.44) MAPTSLC6A2SLC6A4SLC6A3HTR1A
SCHEMBL328393 0.78 MAPT (0.41) MAPTSLC6A2SLC6A4SLC6A3MCL1
SCHEMBL18285488 0.78 SLC6A2 (0.44) MAPTSLC6A2SLC6A4SLC6A3HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3912979-B1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2026-03-25 — — EP disclosed
US-12384786-B2 Cyclic molecules as Bruton's tyrosine kinase inhibitor MINGHUI PHARMACEUTICAL SHANGHAI LTD (CN) 2025-08-12 — — US disclosed
US-20250197402-A1 Tyrosine Kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2025-06-19 — — US disclosed
CN-113149983-B Tyrosine kinase inhibitors 普林斯匹亚生物制药公司 2024-03-29 — — CN disclosed
CN-111454268-B Cyclic molecules as inhibitors of bruton's tyrosine kinase 明慧医药（上海）有限公司 2023-09-08 — — CN disclosed
US-11739090-B2 Substituted pyrazlo[3,4-c]pyridines as selective BTK kinase inhibitors JUMBO DRUG BANK CO., LTD. (CN) 2023-08-29 — — US disclosed
US-11739090-B2 Substituted pyrazlo[3,4-c]pyridines as selective BTK kinase inhibitors JUMBO DRUG BANK CO., LTD. (CN) 2023-08-29 — — US disclosed
CN-116589465-A Cyclic molecules as inhibitors of bruton's tyrosine kinase 明慧医药（上海）有限公司 2023-08-15 — — CN disclosed
US-20230151012-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2023-05-18 — — US disclosed
CN-113710671-B Cyclic molecules as inhibitors of bruton's tyrosine kinase 明慧医药（上海）有限公司 2023-04-28 — — CN disclosed
US-20170152264-A1 AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS Eternity Bioscience Inc. (US) 2017-06-01 — — US disclosed
US-20170152264-A1 AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS Eternity Bioscience Inc. (US) 2017-06-01 — — US disclosed
US-20170129890-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2017-05-11 — — US disclosed
WO-2016196840-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2016-12-08 — — WO disclosed
WO-2016007185-A1 AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS Eternity Bioscience Inc. (US) 2016-01-14 — — WO disclosed
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 — — US disclosed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 — — EP disclosed
EP-2283020-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI Pharmaceuticals, Inc. (US) 2011-02-16 — — EP disclosed
WO-2009143051-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-26 — — WO disclosed
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384786-B2 Cyclic molecules as Bruton's tyrosine kinase inhibitor ABL1, BTK, LYN MAPT 4070/4885LPAR1 2878/4885LPAR5 3185/4885
US-20170129890-A1 TYROSINE KINASE INHIBITORS BTK, LYN, SYK MAPT 3338/4885LPAR1 2276/4885LPAR5 1753/4885
US-20170152264-A1 AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS SSB, MAPKAPK5, BCL9 MAPT 4128/4885LPAR1 1774/4885LPAR5 1307/4885
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES ABL1, TPMT, CYP2C19 MAPT 726/4885LPAR1 4698/4885LPAR5 4699/4885
US-20230151012-A1 TYROSINE KINASE INHIBITORS BTK, LYN, SYK MAPT 3338/4885LPAR1 2276/4885LPAR5 1753/4885
US-11739090-B2 Substituted pyrazlo[3,4-c]pyridines as selective BTK kinase inhibitors BTK, SYK, LCK MAPT 3901/4885LPAR1 1902/4885LPAR5 1984/4885
US-20250197402-A1 Tyrosine Kinase Inhibitors BTK, LYN, SYK MAPT 3338/4885LPAR1 2276/4885LPAR5 1753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.